-
Featured Press Release
Aspira Women’s Health Reports Second Quarter 2021 Financial Results
Learn More -
Press Release
Aspira Women’s Health Inc. Announces Coverage for OVA1® in the AIM Specialty Health Laboratory Medicine Clinical Guidelines
Learn More -
Press Release
Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021
Learn More
Recent News
Choose a Category:
-
May is Mental Health Awareness Month
By: Diane Powis, Ph.D.
Blog
COVID-19 has had a profound impact on the mental health of so many people of all ages. Women diagnosed with ovarian cancer also face an increased risk of mental illness. In fact, according to a recent study, “Women diagnosed with ovarian cancer were more than three times more likely than the general public to be…
-
Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference
Press Release
For a PDF of this press release, click here. AUSTIN, Texas — May 19, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below: William Blair…
-
Aspira Women’s Health Reports First Quarter 2021 Financial Results
Press Release
Conference call scheduled for today, May13 at 4:30 p.m. ET For a PDF of this press release, click here. AUSTIN, Texas — May 13, 2021 — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. “We…
-
Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021
Press Release
For a PDF of this press release, click here. Analytical and Initial Clinical Validation performance for Aspira’s OVASightTM blood-based biomarker test for Ovarian Malignancy risk assessment in women with Adnexal Masses. Data demonstrates the ability to identify Ovarian Cancer Risk in a low prevalence population. AUSTIN, Texas; May 13, 2021 – Aspira Women’s Health, Inc. (Nasdaq:…
-
Aspira Women’s Health Initiates Prospective Clinical Study for Benign Risk Monitoring and High Risk Early Ovarian Cancer Detection with Northwell Health®
Press Release
For a PDF version of this press release, click here. Study Evaluates a 3rd Generation Multivariate Index Assay for serial monitoring women with a benign pelvic mass as well as the expansion of our development of our proteogenomic test for early-stage detection of ovarian cancer in high risk Ovarian Cancer patients. AUSTIN, Texas; May 12, 2021 –…